Manning & Napier Advisors LLC Sells 4,055 Shares of Becton, Dickinson and Company $BDX

Manning & Napier Advisors LLC cut its position in Becton, Dickinson and Company (NYSE:BDX) by 11.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 31,630 shares of the medical instruments supplier’s stock after selling 4,055 shares during the quarter. Manning & Napier Advisors LLC’s holdings in Becton, Dickinson and Company were worth $6,188,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Crossmark Global Holdings Inc. boosted its holdings in Becton, Dickinson and Company by 74.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 16,356 shares of the medical instruments supplier’s stock worth $3,174,000 after buying an additional 7,002 shares during the period. Ethic Inc. raised its holdings in Becton, Dickinson and Company by 9.5% during the fourth quarter. Ethic Inc. now owns 40,970 shares of the medical instruments supplier’s stock valued at $7,951,000 after acquiring an additional 3,568 shares during the period. Strengthening Families & Communities LLC raised its holdings in Becton, Dickinson and Company by 2.4% during the fourth quarter. Strengthening Families & Communities LLC now owns 14,583 shares of the medical instruments supplier’s stock valued at $2,830,000 after acquiring an additional 339 shares during the period. Violich Capital Management Inc. lifted its position in shares of Becton, Dickinson and Company by 2.3% in the fourth quarter. Violich Capital Management Inc. now owns 20,286 shares of the medical instruments supplier’s stock valued at $3,937,000 after acquiring an additional 461 shares in the last quarter. Finally, Generali Asset Management SPA SGR boosted its stake in shares of Becton, Dickinson and Company by 1.1% in the fourth quarter. Generali Asset Management SPA SGR now owns 11,483 shares of the medical instruments supplier’s stock worth $2,229,000 after acquiring an additional 128 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Evercore raised its price target on BDX from $180 to $190, signaling continued confidence in the company’s outlook. Evercore target increase
• Positive Sentiment: Wells Fargo lifted its price target to $161 from $157, suggesting modest upside from current levels. Wells Fargo target increase
• Positive Sentiment: The company’s earnings beat, revenue beat, and higher profit guidance are supporting the stock’s rebound after the report. BD second-quarter fiscal 2026 financial results
• Neutral Sentiment: BD also appointed Vitor Roque as chief financial officer, a management change that is not clearly positive or negative for the stock. BD appoints Vitor Roque CFO
• Neutral Sentiment: Stifel lowered its price target to $175 from $215, which is still above the current share price but reflects a more cautious view. Stifel target cut

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the sale, the director directly owned 36,763 shares of the company’s stock, valued at $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 1,102 shares of company stock worth $198,909 over the last quarter. Insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on BDX shares. Barclays initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price for the company. Piper Sandler dropped their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Argus cut their price objective on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Stifel Nicolaus reduced their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday. Finally, The Goldman Sachs Group started coverage on shares of Becton, Dickinson and Company in a research report on Friday, April 10th. They set a “neutral” rating and a $167.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $184.71.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $149.24 on Friday. The company has a market cap of $42.49 billion, a price-to-earnings ratio of 37.78, a PEG ratio of 10.63 and a beta of 0.22. The firm’s fifty day moving average is $158.49 and its 200 day moving average is $181.08. The company has a quick ratio of 0.58, a current ratio of 0.94 and a debt-to-equity ratio of 0.61. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.32%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same period last year, the company posted $3.35 EPS. The business’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.59 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.8%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.